14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $60.86 $75.66 Friday, 3rd May 2024 CYTK stock ended at $65.27. This is 1.45% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.47% from a day low at $65.00 to a day high of $66.61.
90 days $60.86 $81.33
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
Feb 23, 2023 $41.99 $43.27 $41.57 $43.09 676 281
Feb 22, 2023 $41.74 $42.65 $41.40 $41.74 724 204
Feb 21, 2023 $45.21 $45.50 $41.96 $42.04 1 114 201
Feb 17, 2023 $44.01 $45.84 $43.35 $45.71 601 235
Feb 16, 2023 $42.50 $44.97 $42.30 $44.13 783 720
Feb 15, 2023 $43.05 $43.27 $42.45 $42.87 946 147
Feb 14, 2023 $43.61 $44.36 $42.62 $43.35 744 941
Feb 13, 2023 $43.70 $45.17 $42.32 $43.87 1 108 017
Feb 10, 2023 $44.37 $44.90 $43.56 $43.58 1 073 175
Feb 09, 2023 $44.03 $44.68 $43.45 $44.30 514 906
Feb 08, 2023 $44.98 $44.98 $43.82 $43.89 668 258
Feb 07, 2023 $44.89 $45.10 $43.38 $44.98 625 080
Feb 06, 2023 $45.00 $45.63 $44.62 $44.84 649 438
Feb 03, 2023 $44.00 $45.19 $43.47 $45.01 998 318
Feb 02, 2023 $43.24 $44.86 $42.82 $44.56 983 602
Feb 01, 2023 $42.40 $43.26 $40.83 $42.83 1 063 107
Jan 31, 2023 $41.22 $42.57 $40.94 $42.48 908 743
Jan 30, 2023 $43.08 $43.39 $40.98 $41.06 884 767
Jan 27, 2023 $43.31 $44.03 $43.05 $43.12 405 915
Jan 26, 2023 $43.07 $43.49 $42.45 $43.25 494 630
Jan 25, 2023 $43.21 $43.66 $42.77 $42.96 1 066 624
Jan 24, 2023 $42.23 $43.56 $41.68 $43.15 1 197 866
Jan 23, 2023 $41.88 $42.26 $40.26 $42.20 1 498 768
Jan 20, 2023 $42.41 $42.41 $41.11 $41.79 684 300
Jan 19, 2023 $42.61 $43.19 $41.89 $41.93 776 407
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT